ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 16, 2018--
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology
company focused on degenerative diseases, today announced that it will
be presenting a poster at the Military Health System Research Symposium
(MHSRS) from August 20-23, 2018 in Kissimmee, Florida.
The poster presentation is titled, “Next generation disease modifying
viscosupplementation to delay or prevent invasive surgery in
combat-related Post Traumatic Osteoarthritis (PTOA).” Dr. Thomas
Zarembinski, PhD, MBA and Head of External R&D for BioTime will present
the data on Tuesday, August 21st during the Extremity
and Craniomaxillofacial Regeneration session.
The poster describes the ability of a novel DNA-based small molecule to
decrease cartilage degradation and turnover normally associated with
osteoarthritis as well as the ability of BioTime’s proprietary HyStem®
drug delivery platform to modulate its release over an extended period.
Hystem® is BioTime’s proprietary hydrogel platform that is
designed to facilitate the delivery of cells and molecules. When
delivering molecules, it can slowly release the compound in the target
area over an extended period of time potentially providing several
advantages such as longer term therapeutic benefit. The delivery of
cells and molecules is a core area of focus for BioTime. “The data being
presented is encouraging and allows BioTime to further explore potential
disease modifying therapies for the treatment of osteoarthritis,” said
Dr. Zarembinski, Head of External R&D for BioTime.
About BioTime, Inc.
BioTime is a clinical-stage biotechnology company focused on
degenerative diseases. Its clinical programs are based on two platform
technologies: cell replacement and cell/drug delivery. With its cell
replacement platform, BioTime is producing new cells and tissues with
its proprietary pluripotent cell technologies. These cells and tissues
are developed to replace those that are either rendered dysfunctional or
lost due to degenerative diseases or injuries. BioTime’s cell/drug
delivery programs are based upon its proprietary HyStem® cell
and drug delivery hydrogel matrix technology. HyStem® was
designed, in part, to provide for the transfer, retention and/or
engraftment of cellular replacement therapies. HyStem® is a
unique hydrogel that has been shown to support cellular attachment and
proliferation in vivo. Current research at leading medical institutions
has shown that HyStem® is compatible with a wide variety of
cells and tissue types including brain, bone, skin, cartilage, vascular
and heart tissues. Due to the unique cross-linking chemistry, HyStem®
hydrogels have the ability to mix cells, biologics and small molecule
drugs and can be injected or applied as a gel which allows the hydrogel
to conform to a cavity or space. This property of HyStem®
hydrogels offers several distinct advantages over other hydrogels,
including the possibility of combining bioactive materials with the
hydrogel at the point of use. BioTime is also developing HyStem®
for the delivery of therapeutic drugs and cells to localized areas of
the body, including for sustained drug release in the targeted
anatomical sites. BioTime’s lead cell delivery clinical program is
Renevia®, which consists of HyStem® combined
with the patient's own adipose (fat) derived tissue or cells. Renevia® met
its primary endpoint in an EU pivotal clinical trial for the treatment
of facial lipoatrophy in HIV patients in 2017. BioTime has submitted
Renevia® for CE Mark approval in the EU. There were no device
related serious adverse events reported to date. BioTime’s lead cell
replacement product candidate is OpRegen®, a retinal pigment
epithelium transplant therapy, which is in a Phase I/IIa multicenter
clinical trial for the treatment of dry age-related macular
degeneration, the leading cause of blindness in the developed world.
There have been no unexpected serious adverse events reported to
date. BioTime also has significant equity holdings in two publicly
traded companies, Asterias Biotherapeutics, Inc. (NYSE American: AST)
and OncoCyte Corporation (NYSE American: OCX), and a private
company, AgeX Therapeutics, Inc.
BioTime common stock is traded on the NYSE American and TASE under the
symbol BTX. For more information, please visit www.biotime.com or
connect with the company on Twitter, LinkedIn, Facebook, YouTube,
To receive ongoing BioTime corporate communications, please click on the
following link to join the Company’s email alert list: http://news.biotime.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180816005061/en/
Source: BioTime, Inc.
Investor and Media Contact: